NSAIDs “nonsteroidal anti-inflammatory drugs” previously been linked to increased stroke and heart attack risks, have now been connected with erectile dysfunction (ED) with regular use, says MedScape. The emerging study, a prospective cohort, appeared online last month and in the April print issue of the Journal of Urology. NSAIDs include popular over-the-counter painkillers like Aleve, […]
NSAIDs “nonsteroidal anti-inflammatory drugs” previously been linked to increased stroke and heart attack risks, have now been connected with erectile dysfunction (ED) with regular use, says MedScape. The emerging study, a prospective cohort, appeared online last month and in the April print issue of the Journal of Urology.
NSAIDs include popular over-the-counter painkillers like Aleve, Motrin, Advil, aspirin, and ibuprofen, as well as prescription COX-2 Inhibitors like Celebrex (generic: celecoxib.
The study “the California Men’s Health Study” which was initiated in 2002, enrolled what MedScape described as a “large, ethnically diverse cohort” of men from Kaiser Permanente’s managed care health plans age 45 to 69 years of age. The questionnaire included information on ED and participants auto drug data and self-reported use, which enabled the team to review exposure to NSAIDs, said MedScape.
The study revealed that NSAIDs were present in nearly half of the 80,966 participants “47.4 percent; moderate or severe ED was reported in 29.3 percent, with use of the drugs and ED exhibiting a strong age link”, said MedScape. Also, regular use of the medications increased from 34.5 percent in 45 to 49-year-old men to 54.7 percent in 60 to 69-year-old men, with a collaborative ED increase of 13 to 42 percent, noted MedScape. The link remained after adjustments for age; race; ethnic background; smoking habits; diagnoses for “diabetes mellitus, hypertension, hyperlipidemia, peripheral vascular disease, or coronary artery disease”; and body mass index, MedScape explained.
“These data suggest that regular NSAID use is associated with ED even after extensive adjustment for age and potentially confounding factors or comorbidities,” the study authors wrote. ”
In 2004, the COX-2 inhibitor rofecoxib (Vioxx) was withdrawn from the market after a trial found that the drug increased risks for cardiovascular disease. Since, there has been much debate about the cardiovascular safety of COX-2 inhibitors and traditional NSAIDs. NSAIDs are the most popular medication, with five percent of all physician visits in the U.S. involving a prescription for an NSAID, noted Arthritis Today previously.